Holland Lab

115. Patrick A. Cieslik, Dominik Roth, Eda Nisli, Jonas Genz, Cesare Berton, Pascal V. Grundler, Colin C. Hillhouse, Anzhelika N. Moiseeva, Mirja Nolff, Henrik Braband, Nicholas P. van der Meulen, and Jason P. Holland*; Photoradiosynthesis of 161Tb-labelled onartuzumab for radioimmunotherapy of gastric adenocarcinoma; JACS Au, 2025, in press

​

114. Jonas Genz, Cesare Berton, Samy Kichou, Simon Klingler, Mirja C. Nolff, Henrik Braband and Jason P. Holland*; Photoradiolabeling of onartuzumab with 99mTc and 188Re-tricarbonyl for radiotheranostics of gastric cancer; Chem. Sci., 2025, 6, 6219–6230. Highlighted as the ‘Cover feature’. DOI: 10.1039/D4SC08089K. From the themed collection: 2025 Chemical Science Covers.

 

113. Cesare Berton and Jason P. Holland*; Light-induced chemistry for protein functionalisation; Chem. Commun., 2025, 61, 5234–5252.Highlighted as the ‘Cover feature’. DOI: 10.1039/D4CC06529H. Part of the themed collection: 2025 Pioneering Investigators.

 

112. Cesare Berton, Simon Klingler, Stanislav Prytuliak and Jason P. Holland*; New tactics in the design of theranostic radiotracers; NPJ Imaging, 2024, 2(23), 1–15. DOI: 10.1038/s44303-024-00027-1.

 

111. Patrick Cieslik, Simon Klingler, Mirja Nolff and Jason P. Holland*; Radiolabelled 177Lu-bispidine-trastuzumab for targeting human epidermal growth factor receptor 2 positive cancers; Chem. Eur. J., 2024, e202303805. DOI: 10.1002/chem.202303805.

 

110. Steven Archibald, Jason P. Holland, Aruna Korde, Andre F. Martins, Adam J. Shuhendler and Peter J. H. Scott*; Combining nuclear medicine with other modalities: future prospect for multimodality imaging; Mol. Imaging, 2024, 23(1), 1–15. DOI: 10.1177/15353508241245265.

 

109. Moritz-Valentin Schreck, Caroline Burgard, Alexander Schmidtke, Ina Hierlmeier, Tobias Stemler, Stephan Maus, Florian Rosar, Martin Jung, Samer Ezziddin, Jason P. Holland, and Mark D. Bartholomä*; Radiometal complexes as pharmacokinetic modifiers: A potent 68Ga-labeled gastrin-releasing peptide receptor antagonist based on the macrocyclic metal chelator NODIA-Me; Mol. Pharmaceutics, 2023, 20(12), 6463–6473. DOI: 10.1021/acs.molpharmaceut.3c00852.

 

108. Ina Hierlmeier, Amaury Guillou*, Daniel F. Earley, Anthony Linden, Jason P. Holland and Mark D. Bartholomä*; HNODThia: a promising chelator for the development of 64Cu-radiopharmaceuticals; Inorg. Chem., 2023, 62(50), 20677–20687. DOI: 10.1021/acs.inorgchem.3c01616.

 

107. Lavinia E. Chiti,* Brian Park, Faustine d’Orchymont, Jason P. Holland and Mirja C. Nolff; Impact of surgical lights on the performances of fluorescence guided surgery systems: a pilot study; Animals, 2023, 13(14), 2363. DOI: 10.3390/ani13142363.

 

106. Lavinia E. Chiti*, Benjamin Husi, Brian Park, Patricia Beer, Faustine D’Orchymont, Jason P. Holland and Mirja C. Nolff; Performance of two clinical fluorescence imaging systems with different targeted and non-targeted near-infrared fluorophores: a cadaveric explorative study; Frontiers Vet. Sci., 2023, 10, 1-10. DOI: 10.3389/fvets.2023.1091842.

 

105. Melanie Gut, Birgit Dreier, Sven Furler, Jens Sobek, Andreas Plückthun and Jason P. Holland*; Designed Ankyrin Repeat Proteins for detecting prostate-specific antigen expression in vivo; RSC Chem. Biol., 2023, 4, 494-505. DOI: 10.1039/d3cb00010a.

 

104. Faustine d’Orchymont and Jason P. Holland*; Cooperative capture synthesis of functionalised heterorotaxanes – chemical scope, kinetics and mechanistic studies; J. Am. Chem. Soc., 2023, 145(23), 12894–12910. DOI: 10.1021/jacs.3c04111.

 

103. Faustine d’Orchymont and Jason P. Holland*; Asymmetric rotaxanes as dual-modality supramolecular imaging agents for targeting cancer biomarkers; Commun. Chem., 2023, 6, 107. DOI: 10.1038/s42004-023-00906-5.

 

102. Faustine d’Orchymont and Jason P. Holland*; A rotaxane-based platform for tailoring the pharmacokinetics of cancer-targeted radiotracers; Chem. Sci., 2022, 13, 12713-12725. DOI: 10.1039/D2SC03928A.

 

101. Amaury Guillou, Ali Ouadi and Jason P. Holland*; Heptadentate chelates for 89Zr-radiolabelling of monoclonal antibodies; Inorg. Chem. Frontiers, 2022, 9, 3071. DOI: 10.1039/D2QI00442A.

 

100. Faustine d’Orchymont and Jason P. Holland*; Supramolecular rotaxane-based multi-modal probes for cancer biomarker imaging; Angew. Chemie. Int. Ed., 2022, e202204072. DOI: 10.1002/anie.202204072. Highlighted as a ‘Hot Paper’ 05/2022. Highlighted as a ‘Science Concentrate’ in Chimia 2022, 76(7/8), 700. 

 

99. Rachael Fay, Imre Törő, Anna-Lena Schinke, Branko Simic, Jonas V. Schäfer, Birgit Dreier, Andreas Plückthun and Jason P. Holland*;Enzyme-mediated site-specific conjugation and 89Zr-radiolabeling of designed ankyrin repeat proteins for PET; Mol. Pharmaceutics, 2022, 19(10), 3576-3585. DOI: 10.1021/acs.molpharmaceut.2c00136.

 

98. Daniel F. Earley,† Jose Esteban Flores,† Amaury Guillou and Jason P. Holland*; Photoactivatable bis(thiosemicarbazone) derivatives for copper-64 radiotracer synthesis; Dalton Trans., 2022, 21, 5041. DOI: 10.1039/D2DT00209D. Selected by the editor as a ‘Hot Paper’ 050422.

 

97. Daniel F. Earley,† Amaury Guillou,† Simon Klingler, Rachael Fay, Melanie Gut, Faustine d’Orchymont, Shamisa Behmaneshfar, Linus Reichert and Jason P. Holland*; Charting the chemical and mechanistic scope of light-triggered protein ligation; JACS Au, 2022, 2(3), 646-664. DOI: 10.1021/jacsau.1c00530.

 

96. Simon Klingler and Jason P. Holland*; Automated light-induced synthesis of 89Zr-radiolabeled antibodies for immuno-positron emission tomography; Sci. Reports, 2022, 12, 668. DOI: 10.1038/s41598-021-04626-5.

 

95. Amaury Guillou, Eda Nisli, Simon Klingler, Anthony Linden and Jason P. Holland*; Photoactivatable fluorescent tags for dual-modality PET-optical imaging; J. Med. Chem., 2022, 65, 811-823. DOI: 10.1021/acs.jmedchem.1c01899.

 

94. Nikita Podvalnyy, Serge Chesnov, Paolo Nanni, Melanie Gut, Jason P. Holland and Thierry Hennet*; Synthesis of photoactivable oligosaccharide derivatives from 1,2-cyclic carbamate building blocks and study of their interaction with carbohydrate-binding proteins; Carbohydrate Res., 2021, 508, 108399. DOI: 10.1016/j.carres.2021.108399.

 

93. Amaury Guillou,† Daniel F. Earley,† Simon Klingler, Eda Nisli, Laura Nüesch, Rachael Fay, and Jason P. Holland*; The influence of polyethylene glycol linkers on the metabolism and pharmacokinetics of 89Zr-radiolabeled antibodies; Bioconjugate Chem., 2021, 32(7), 1263–1275. DOI: 10.1021/acs.bioconjchem.1c00172.

 

92. Sebastian Martin, Roswitha Tönnesmann, Ina Hierlmeier, Stephan Maus, Florian Rosar, Juri Ruf, Jason P. Holland, Samer Ezziddin and Mark D. Bartholomä*; Identification, characterization and suppression of side products formed during the synthesis of [177Lu]Lu-PSMA-617; J. Med. Chem., 2021, 64(8), 4960–4971. DOI: 10.1021/acs.jmedchem.1c00045.

 

91. Jennifer Lamb, Joris Šimaitis, Siriney O. Halukeerthi, Christoph G. Salzmann and Jason P. Holland*; Graphene nanoflake antibody conjugates for multi-modal imaging of tumors; Adv. NanoBiomed. Res., 2021, 2100009. DOI: 10.1002/anbr.202100009.

 

90. Daniel F. Earley Amaury Guillou, Dion van der Born, Alex J. Poot and Jason P. Holland*; Microfluidic preparation of 89Zr-radiolabelled proteins by flow photochemistry; Molecules, 2021, 26(3), 764. DOI: 10.3390/molecules26030764.

 

89. Simon Klingler and Jason P. Holland*; Computational studies on the Carboni-Lindsey reaction; Comput. Theor. Chem., 2021, 1197, 113161. DOI: 10.1016/j.comptc.2021.113161. 

 

88. Rachael Fay and Jason P. Holland*; Tuning tetrazole photochemistry for protein ligation and molecular imaging; Chem. Eur. J., 2021, 27, 4893-4897. DOI: 10.1002/chem.202100061.

 

87. Jennifer Lamb, Faustine d’Orchymont, Rachael Fay, Florian Gribi, Jose Esteban Flores, Melanie Gut, Simon Klingler, Patricia Pires, Jan Bühler, Shamisa Behmaneshfar, Amaury Guillou, Daniel F. Earley and Jason P. Holland*; Expanding the chemistry palette for radiotracer synthesis; Chimia, 2020, 74(12), 946-952. Highlighted as the Front Cover. DOI: 10.2533/chimia.2020.946.

 

86. Sebastian Martin, Stephan Maus, Tobias Stemler, Florian Rosar, Fadi Khreish, Jason P. Holland, Samer Ezziddin and Mark D. Bartholomä*; Proof-of-concept study of the NOTI chelating platform: Preclinical evaluation of 64Cu-labeled mono- and trimeric c(RGDfK) conjugates; Mol. Imaging Biol., 2020, (23), 95-108. DOI: 10.1007/s11307-020-01530-8.

 

85. Amaury Guillou, Daniel F. Earley, Malay Patra and Jason P. Holland*; Light-induced synthesis of protein conjugates and its application in photoradiosynthesis of 89Zr-radiolabelled monoclonal antibodies; Nature Protocol, 2020, 15, 3579–3594. DOI: 10.1038/s41596-020-0386-5.

 

84. Amaury Guillou, Daniel F. Earley, Jason P. Holland*; Light-activated protein-conjugation and 89Zr-radiolabelling with water-soluble desferrioxamine derivatives; Chem. Eur. J., 2020, 26, 7185-7189. DOI: 10.1002/chem.202001755. Highlighted as the ‘Cover Feature’.

 

83. Rachael Fay, Anthony Linden and Jason P. Holland*; PhotoTag – photoactivatable fluorophores for protein labelling; Org. Lett., 2020, 22(9), 3499-3503. DOI: 10.1021/acs.orglett.0c00957. 

 

82. Cassis Varlow, Emily Murrell, Jason P. Holland, Alina Kassenbrock, Whitney Shannon, Steven H. Liang, Neil Vasdev* and Nickeisha A. Stephenson*; Revisiting the Radiosynthesis of [18F]FPEB and Preliminary PET Imaging in a Mouse Model of Alzheimer’s Disease; Molecules, 2020, 25(4), 982. DOI: 10.3390/molecules25040982.

 

81. Jason P. Holland*; Predicting the thermodynamic stability of zirconium radiotracers; Inorg. Chem., 2020, 59, 2070-2082. DOI:10.1021/acs.inorgchem.9b03515.

 

80. Simon Klingler, Rachael Fay and Jason P. Holland*; Light-induced radiosynthesis of 89ZrDFO-azepin-onartuzumab for imaging the hepatocyte growth factor receptor; J. Nucl. Med., 2020, 61, 1072-1078. DOI: 10.2967/jnumed.119.237180.

 

79. Jason P. Holland*, Melanie Gut, Simon Klingler, Rachael Fay and Amaury Guillou; Photochemical reactions in the synthesis of protein-drug conjugates; Chem. Eur. J., 2020, 26, 33-48. DOI: 10.1002/chem.201904059.

 

78. Angelo Frei,* Eliane Fischer, Bradley Childs, Jason P. Holland and Roger Alberto; Two is better than one: dimeric high-affinity PSMA probes based on a [CpM(CO)3] (M = Re/99mTc) scaffold; Dalton Trans., 2019, 48, 14600-14605. DOI: 10.1039/C9DT02506E.

 

77. Jason P. Holland*; Radiochemistry and drug synthesis ‘in a flash’; Drug Target Rev., 2019, 2, 31-34. Link.

 

76. Melanie Gut and Jason P. Holland*; Synthesis and photochemical studies on gallium and indium complexes of DTPA-PEG3-ArN3 for radiolabelling antibodies; Inorg. Chem., 2019, 58(18), 12302-12310. DOI: 10.1021/acs.inorgchem.9b01802.

 

75. Jennifer Lamb, Eliane Fischer, Martin Rosillo-Lopez, Christoph G. Salzmann and Jason P. Holland*; Multi-functionalised graphene nanoflakes as tumour-targeting theranostic drug-delivery vehicles; Chem. Sci., 2019, 10, 8880-8888. DOI: 10.1039/C9SC03736E. Highlighted in a press release by the SNSF, and as a ‘Science Concentrate’ in Chimia 2019.

 

74. Christopher J. M. Brown, Michael P. Gotsbacher, Jason P. Holland, and Rachel Codd*; Endo-Hydroxamic acid monomers for the assembly of a suite of non-native dimeric macrocyclic siderophores using metal-templated synthesis; Inorg. Chem., 2019, 58, 13591-13603. DOI: 10.1021/acs.inorgchem.9b00878.

 

73. Rachael Fay, Melanie Gut and Jason P. Holland*; Photoradiosynthesis of 68Ga-labeled HBED-CC-azepin-MetMAb for immuno-PET of c‐MET receptors; Bioconjugate Chem., 2019, 30, 1814-1820. DOI: 10.1021/acs.bioconjchem.9b00342.

 

72. Rachael Fay and Jason P. Holland*; The impact of emerging bioconjugation chemistries on radiopharmaceuticals; J. Nucl. Med., 2019, 60, 587-591. DOI: 10.2967/jnumed.118.220806.

 

71. Malay Patra, Simon Klingler, Larissa S. Eichenberger and Jason P. Holland*; Simultaneous photoradiochemical labeling of antibodies for immuno-positron emission tomography; iScience (Cell Press), 2019, 13, 416-431. DOI: 10.1016/j.isci.2019.03.004. 

70. Larissa S. Eichenberger, Malay Patra and Jason P. Holland*; Photoactive chelates for radiolabelling proteins; Chem. Commun., 2019, 55, 2257-2260. DOI: 10.1039/C8CC09660K. Highlighted as the Front Cover.

 

69. Malay Patra, Larissa S. Eichenberger, Gregor Fischer and Jason P. Holland*; Photochemical conjugation and one-pot radiolabelling of antibodies for immuno-PET; Angew. Chem. Int. Ed., 2019, 58, 1928-1933. DOI: 10.1002/anie.20181328 and 10.1002/ange.201813287. Highlighted as the ‘Frontispiece’. 

 

68. Christian Weinmann, Jason P. Holland, Tilman Läppchen, Harald Scherer, Stephan Maus, Tobias Stemler, Hendrik Bohnenberger, Samer Ezziddin, Philipp Kurz* and Mark D. Bartholomä*; Optimized synthesis and indium complex formation with the bifunctional chelator NODIA-Me; Org. Biomol. Chem., 2018, 16, 7503-7512. DOI: 10.1039/c8ob01981a.

 

67. Jason P. Holland*; Chemical kinetics of radiolabelling reactions; Chem. Eur. J., 2018, 24, 16472-16483. DOI: 10.1002/chem.201803261. Highlighted as the ‘Frontispiece’: DOI: 10.1002/chem.201886262.

 

66. Tilman Läppchen, Yvonne Kiefer, Jason P. Holland and Mark Bartholomä*; Preparation and preclinical evaluation of a 68Ga-labelled c(RGDfK) conjugate comprising the bifunctional chelator NODIA-Me; Eur. J. Nucl. Med. Mol. Imaging Radiopharm. Chem., 2018, 3(6), 1-11. DOI: 10.1186/s41181-018-0043-2.

 

65. Tilman Läppchen, Yvonne Kiefer, Jason P. Holland and Mark Bartholomä*; In vitro and in vivo evaluation of the bifunctional chelator NODIA-Me in combination with a prostate specific membrane antigen targeting vector; Nucl. Med. Biol., 2018, 60, 45-54. DOI: 10.1016/j.nucmedbio.2018.03.002. 

 

64. Thomas L. Collier,* Kenneth Dahl, Nickeisha A. Stephenson, Jason P. Holland, Adam Riley, Steven H. Liang and Neil Vasdev; Recent applications of a single quadrupole mass spectrometer in PET radiochemistry; J. Fluorine Chem., 2018, 210, 46-55. DOI: 10.1016/j.jfluchem.2018.02.009.

 

63. Eszter Boros* and Jason P. Holland*; Chemical aspects of metal ion chelation in the synthesis and application antibody‐based radiotracers; J. Labelled Compounds Radiopharm., 2018, 61, 652-671. DOI: 10.1002/jlcr.3590.

 

62. Jennifer Lamb and Jason P. Holland*; Advanced methods for radiolabelling multi-modality nanomedicines for SPECT/MRI and PET/MRI; J. Nucl. Med., 2018, 59, 382-389. DOI:10.2967/jnumed.116.187419.

 

61. Eleni Gourni, Luigi Del Pozzo, Mark Bartholomä, Yvonne Kiefer, Philipp T. Meyer, Helmut R. Maecke, and Jason P. Holland*; Radiochemistry and PET imaging of 68Ga-desferrioxamine radiotracers targeting prostate-specific membrane; Mol. Imaging, 2017, 16, 1-11. DOI: 10.1177/1536012117737010. 

 

60. Alexander Schmidtke, Tilman Läppchen, Christian Weinmann, Lorenz Bier-Schorr, Manfred Keller, Yvonne Kiefer, Jason P. Holland and Mark D. Bartholomä*; Gallium complexation, stability and bioconjugation of TACN derived chelators with azaheterocyclic arms; Inorg. Chem., 2017, 56(15), 9097-9110. DOI: 10.1021/acs.inorgchem.7b01129.

 

59. Jason P. Holland*; The role of molecular imaging in personalised healthcare; Chimia, 2016, (9), 787-795. DOI: 10.2533/chimia.2016.787.

 

Articles prior to joining UZH

 

58. Eszter Boros,* Jason P. Holland, Nathaniel Kenton, Nicholas Rotile and Peter Caravan; Macrocycle-based hydroxamate ligands for stable complexation and immunoconjugation of the PET Isotope 89Zr; ChemPlusChem, 2016, 81(3), 274-281. DOI: 10.1002/cplu.201600003.

 

57. Svetlana N. Rylova,* Luigi Del Pozzo, Roswitha Tönnesmann, Anna-Lena Illert, Philipp T. Meyer, Helmut R. Maecke and Jason P. Holland; Immuno-PET imaging of CD-30 positive lymphoma using 89Zr-DFO-AC-10; J. Nucl. Med., 2016, 57, 96-102. DOI: 10.2967/jnumed.115.162735.

 

56. David E. Hill and Jason P. Holland*; Computational studies on hypervalent iodonium(III) compounds as activated precursors for 18F radiofluorination of electron-rich arenes; Comput. Theor. Chem., 2015, 1066, 34-56. DOI: 10.1016/j.comptc.2015.05.012.

 

55. Steven H. Liang,† Jason P. Holland,† Nickeisha A. Stephenson, Alina Kassenbrock, Benjamin H. Rotstein, Cory Daignault, Rebecca Lewis, Thomas Lee Collier, Jacob M. Hooker and Neil Vasdev*; PET neuroimaging studies of [18F]CABS13 in a double transgenic mouse model of Alzheimer’s disease and nonhuman primates; ACS Chem. Neurosci., 2015, 6, 535-541. DOI: 10.1021/acschemneuro.5b00055. 

 

54. Nickeisha A. Stephenson, Jason P. Holland, Alina Kassenbrock, Daniel L. Yokell, Steven H. Liang and Neil Vasdev*; Iodonium ylide mediated radiofluorination of 18F-FPEB and validation for human use; J. Nucl. Med., 2015, 56, 489-492. DOI: 10.2967/jnumed.114.151332.

 

53. David E. Hill, Neil Vasdev and Jason P. Holland*; Evaluating the accuracy of density functional theory for calculating 1H and 13C NMR chemical shifts in drug molecules; Comput. Theor. Chem., 2015, 1051, 161-173. DOI:10.1016/j.comptc.2014.11.007.

 

52. Eszter Boros, Alice M. Bowen, Lee Josephson, Neil Vasdev and Jason P. Holland*; Chelate-free metal ion binding and heat-induced radiolabeling of iron oxide nanoparticles; Chem. Sci., 2015, 6(1), 225-236. DOI: 10.1039/C4SC02778G.

 

51. Jason P. Holland* and Neil Vasdev; Charting the mechanism and reactivity of zirconium oxalate with hydroxamate ligands using density functional theory: implications in new chelate design; Dalton Trans., 2014, 43, 9872-9884. DOI: 10.1039/C4DT00733F. Highlighted as the “Cover Picture,” July 2014.

 

50. Eszter Boros,* Elena Rybak-Akimova, Jason P. Holland, Tyson Rietz, Nicholas Rotile,  Francesco Blasi,  Helen Day, Peter Müller and Peter Caravan*; Pycup – A bifunctional, cage-like ligand for 64Cu radiolabeling; Mol. Pharmaceuticals, 2014, 1(2), 617-629. DOI: 10.1021/mp400686z.

 

49. Neeta Pandit-Taskar,† Joseph A. O’Donoghue,† Volkan Beylergil, Serge Lyaschenko, Shutian Ruan, Steven B. Solomon, Jeremy C. Durack, Jorge A. Carrasquillo, Robert A. Lefkowitz, Mithat Gonen, Jason S. Lewis, Jason P. Holland, Sarah M. Cheal, Victor E. Reuter, Joseph R. Osborne, Massimo F. Loda, Peter M. Smith-Jones, Wolfgang A. Weber, Neil H. Bander, Howard I. Scher, Michael J. Morris* and Steven M Larson*; 89Zr J591 immunoPET imaging in patients with castration-resistant prostate cancer; Eur. J. Nucl. Med. Mol. Imaging, 2014, 41, 2093-2105. DOI: 10.1007/s00259-014-2830-7.

 

48. Jason P. Holland, Steven H. Liang, Benjamin H. Rotstein, Thomas Lee Collier, Nickeisha A. Stephenson, Ivan Greguric and Neil Vasdev*; Alternative approaches for PET radiotracer development in Alzheimer’s disease: Imaging beyond plaque; J. Labelled Compds Radiopharm., 2014,57, 323-331. Highlighted as the “Cover Picture”. 2014. DOI: 10.1002/jlcr.3158.

 

47. Benjamin H. Rotstein, Steven H. Liang, Jason P. Holland, Thomas Lee Collier, Jacob M. Hooker, Alan A. Wilson and Neil Vasdev*; 11CO2Fixation: A renaissance in PET radiochemistry; Chem. Commun., 2013, 49, 5621-5629. DOI: 10.1039/C3CC42236D. Highlighted as the “Cover Picture”. 2013.

 

46. Jason P. Holland,* Albert Kang, Susan Cohrs, Svetlana V. Selivanova, Selena Milicevic Sephton, Thomas Betzel, Daniel Frey, Mara Wieser, Rolf Jaussi, Richard A. Kammerer, Roger Schibli and Eliane Fischer*; Synthesis and evaluation of biphenyl derivatives as kinesin spindle protein inhibitors; Chem. Biodiversity, 2013, 10(4), 538-555. DOI: 10.1002/cbdv.201200400.

 

45. Yelena Y. Janjigian,†* Nerissa Viola-Villegas,† Jason P. Holland, Vadim Divilov, Greg Carbonetti, Sean Carlin, Erica M. Gomes DaGama, Gabriela Chiosis, Elisa de Stanchina and Jason S. Lewis*; Monitoring afatinib treatment in HER2 positive gastric cancer with 18F-FDG and 89Zr-trastuzumab PET; J. Nucl. Med., 2013, 54, 936-943. DOI: 10.2967/jnumed.112.110239. Featured in a “Health Imaging” press release. 

 

44. Jason P. Holland,* Michael W. Jones, Susan Cohrs, Roger Schibli and Eliane Fischer*; Fluorinated quinazolinones as potential radiotracers for imaging kinesin spindle protein expression; Bioorg. Med. Chem., 2013, 21, 496-507. DOI: 10.1016/j.bmc.2012.11.013.

 

43. Jason P. Holland, Paul Cumming and Neil Vasdev*; PET imaging of enzymes in the brain; Amer. J. Nucl. Med. Mol. Imaging, 2013, 3(3), 194-216. Link.

 

42. Michael J. Evans, Jason P. Holland, Michael G. Doran, Sarah M. Cheal, Carl Campos, Samuel L. Rice, Sean Carlin, Ingo K. Mellinghoff, Charles L. Sawyers and Jason S. Lewis; Imaging tumor burden in the brain with 89Zr-transferrin; J. Nucl. Med., 2013, 54(1), 90-95. DOI: 10.2967/jnumed.112.109777. Highlighted as the “Cover Picture,” January 2013.

 

41. Jason P. Holland,† Michael J. Evans,† Samuel L. Rice, John Wongvipat, Charles L. Sawyers* and Jason S. Lewis*; Annotating MYC status with 89Zr-transferrin imaging; Nature Med., 2012, 18, 1586-1591. DOI: 10.1038/nm.2935. Featured in a SciBX press release.

 

40. David Ulmert,† Michael J. Evans,† Jason P. Holland, Samuel L. Rice, John Wongvipat, Kim Pettersson, Per-Anders Abrahamsson, Peter T. Scardino, Steven M. Larson, Hans Lilja, Jason S. Lewis* and Charles L. Sawyers*; Imaging androgen receptor signaling with a radiotracer targeting prostate specific antigen; Cancer Discovery, 2012, 2(4), 320-327. DOI: 10.1158/2159-8290.CD-11-0316. Highlighted as the “Cover Picture,” April 2012. Featured in an AACR video press conference and in a “Spotlight” article.

 

39. Jason P. Holland,* Paul Cumming and Neil Vasdev; PET of signal transduction pathways in cancer; J. Nucl. Med., 2012, 53(9), 1333-1336. DOI: 10.2967/jnumed.112.105387.

 

38. Linjing Mu, Cindy R. Fischer, Jason P. Holland, Jessica Becaud,  P. August Schubiger,  Roger Schibli,  Simon M. Ametamey,*  Keith Graham, Timo Stellfeld,  Ludger M. Dinkelborg and Lutz Lehmann; 18F-radiolabeling of aromatic compounds using triarylsulfonium salts; Eur. J. Org. Chem., 2012, 2012(5), 889-892. DOI: 10.1002/ejoc.201101730.

 

37. Alessandro Ruggiero,† Jason P. Holland,† Tvrtko Hudolin,† Larissa Shenker, Anna Koulova, Neil H. Bander, Jason S. Lewis and Jan Grimm*; PET imaging of therapy-induced prostate cancer cell death by targeting the internal epitope of prostate specific membrane antigen; J. Nucl. Med., 2011, 52(10), 1608-1615. DOI: 10.2967/jnumed.111.092098.

 

36. Jason P. Holland, Guillaume Normand, Alessandro Ruggiero, Jason S. Lewis and Jan Grimm*; Intra-operative imaging of PET radiotracers using Cerenkov luminescence emissions; Mol. Imaging, 2011, 10(3), 177-186. DOI: 10.2310/7290.2010.00047.

 

35. Carola Heneweer,† Jason P. Holland,† Vadim Divilov, Sean Carlin and Jason S. Lewis*; Magnitude of enhanced permeability and retention (EPR) effect in tumors with different phenotypes: 89Zr-albumin as a model system; J. Nucl. Med., 2011, 52(4), 625-633. DOI: 10.2967/jnumed.110.083998.

 

34. Alessandro Ruggiero,† Carlos H. Villa,† Jason P. Holland, Shanna R. Sprinkle, Chad May, Jason S. Lewis, David A. Scheinberg and Michael R. McDevitt*; Imaging and treating tumor vasculature with radiolabeled carbon nanotubes; Int. J. Nanomedicine, 2010, 5, 783-802. DOI: 10.2147/IJN.S13300.

 

33. Inmaculada Matas Ruiz, George R. Whittell, Benjamin M. Partridge, Jason P. Holland, Mairi F. Haddow, Jennifer C. Green* and Ian Manners*; Synthesis, electronic structure, and reactivity of nickel-, palladium-, and platinum-bridged [1]ferrocenophanes; J. Amer. Chem. Soc., 2010, 132(38), 13279-13289. DOI: 10.1021/ja103367e.

 

32. Jason P. Holland and Jason S. Lewis*; Zirconium-89 chemistry in the design of novel radiotracers for immuno-PET; Technetium and Other Radiometals in Chemistry and Medicine, Eds: Ulderico Mazzi, William C. Eckelman, Wynn A. Volkert, Publisher: Servizi Grafici Editoriali snc, Padova, Italy, 2010, 187-192.

 

31. Jason P. Holland, Vadim Divilov, Neil H. Bander, Peter M. Smith-Jones, Steven M. Larson and Jason S. Lewis*; 89Zr-DFO-J591 for immunoPET of prostate-specific membrane antigen expression in vivo; J. Nucl. Med., 2010, 51(8), 1293-1300. DOI: 10.2967/jnumed.110.076174. Selected as the Journal of Nuclear Medicine’s Editor’s Choice Award for the “Best Basic Science Article,” June 2011.

 

30. Alessandro Ruggiero,† Jason P. Holland,† Jason S. Lewis and Jan Grimm*; Cerenkov luminescence imaging of medical isotopes; J. Nucl. Med., 2010, 51(7), 1123-1130. DOI: 10.2967/jnumed.110.076521. Highlighted in a press release by the Society of Nuclear Medicine.

 

29. Martin Christlieb,* Jason P. Holland and Jonathan R. Dilworth; Investigation of the UV–Vis absorption of bis(N-methylthiosemicarbazonato) zinc Zn[ATSM]; Inorganica Chim. Acta, 2010, 363(6), 1133-1139. DOI: 10.1016/j.ica.2009.10.006.

 

28. Artem Y. Lebedev, Jason P. Holland and Jason S. Lewis*; Clickable bifunctional radiometal chelates for peptide labeling; Chem. Commun., 2010, 46, 1706-1708. DOI: 10.1039/b924784j.

 

27. Jason P. Holland,* and Jennifer C. Green; Evaluation of exchange-correlation functionals for time-dependent density functional theory calculations on metal complexes; J. Comput. Chem., 2010, 31(5), 1008-1014. DOI: 10.1002/jcc.21385.

 

26. John G. Woollard-Shore, Jason P. Holland, Michael W. Jones* and Jonathan R. Dilworth*; Nitrite reduction by copper complexes; Dalton Trans., 2010, 39(6), 1576-1585. DOI: 10.1039/b913463h.

 

 

25. Jason P. Holland, Eloisi Caldas-Lopes, Vadim Divilov, Valerie M. Longo, Tony Taldone, Danuta Zatorska, Gabriela Chiosis and Jason S. Lewis*; Measuring the pharmacodynamic effects of a novel Hsp90 inhibitor on HER2/neu expression in mice using 89Zr-DFO-trastuzumab; PLoS ONE, 2010, 5(1), e8859. DOI: 10.1371/journal.pone.0008859.

 

24. Jason P. Holland,* Victoria Fisher, Jennie A. Hickin and Josephine M. Peach*; Pyrene-functionalised copper complexes as potential dual-modality imaging agents; Eur. J. Inorg. Chem., 2010, (1), 48-58. DOI: 10.1002/ejic.200900823. Highlighted as the “Cover Picture,” January 2010.

 

23. Jason P. Holland, Matthew J. Williamson and Jason S. Lewis*; Unconventional nuclides for radiopharmaceuticals; Mol. Imaging, 2010, 9(1), 1-20. DOI: 10.2310/7290.2010.00008.

 

22. Jason P. Holland,* Michael W. Jones, Paul D. Bonnitcha, Jason S. Lewis and Jonathan R. Dilworth; Functionalised copper-64 bis(thiosemicarbazonato) complexes as precursors of potential PET imaging agents for neurodegenerative disorders; New J. Chem., 2009, 33, 1845-1852. DOI: 10.1039/b902895a. Top 10 New J. Chem. downloaded articles, September 2009.

 

21. Jason P. Holland, Yiauchung Sheh and Jason S. Lewis*; Standardized methods for the production of high specific-activity zirconium-89; Nucl. Med. Biol., 2009, 36, 729-739. DOI: 10.1016/j.nucmedbio.2009.05.007. 

 

20. Peter J. Barnard,* Jason P. Holland, Simon R. Bayly, Thaddeus J. Wadas, Carolyn J. Anderson and Jonathan R. Dilworth*; Macrocyclic diamide ligand systems: potential chelators for 64Cu- and 68Ga-based positron emission tomography imaging agents; Inorg. Chem., 2009, 48(15), 7117-7126. DOI: 10.1021/ic900307f.

 

19. Georgeta Masson, David E. Herbert, George R. Whittell, Jason P. Holland, Alan J. Lough, Jennifer C. Green* and Ian Manners*; Synthesis and reactivity of a silicon-bridged [1]ferroceniumphane; Angew. Chem. Int. Ed., 2009, 48, 4961-4964. DOI: 10.1002/anie.200901213.

 

18. Franziska Bell, Jason Holland, Jennifer C. Green* and Michel R. Gagné; Computational studies on the Pt(II)-catalyzed cycloisomerization of 1,6-dienes into bicyclopropanes: A mechanistic quandary evaluated by DFT; Organometallics, 2009, 28, 2038-2045. DOI: 10.1021/om800770x.

 

17. Jason P. Holland,* Jeffrey H. Giansiracusa, Stephen G. Bell, Luet-Lok Wong and Jonathan R. Dilworth; In vitro kinetic studies on the mechanism of oxygen-dependent cellular uptake of copper radiopharmaceuticals; Phys. Med. Biol., 2009, 54, 2103-2119. DOI: 10.1088/0031-9155/54/7/017.

 

16. Jason P. Holland,* Peter J. Barnard, Simon R. Bayly, Jonathan R. Dilworth and Jennifer C. Green; Electronic absorption spectroscopy and time-dependent density functional theory calculations on the nickel(II) complex of 1,4-bis(pyrrol-2-ylmethyleneamino)butane; Inorganica Chim. Acta, 2009, 362(2), 402-406. DOI: 10.1016/j.ica.2008.04.031.

 

15. Jason P. Holland, Riccardo Ferdani, Carolyn J. Anderson and Jason S. Lewis*; Copper-64-radiopharmaceuticals for oncologic imaging; PET Clinics, 2009, 4(1), 49-67. DOI: 10.1016/j.cpet.2009.04.013.

 

14. Jason P. Holland, Jason S. Lewis and Farrokh Dehdashti*; Assessing tumor hypoxia by positron emission tomography with Cu-ATSM; Q. J. Nucl. Med. Mol. Imaging, 2009, 53, 193-200. Link.

 

13. Jason P. Holland,* Jennie A. Hickin, Emma Grenville-Mathers, ThaoNguyen Nguyen, and Josephine M. Peach*; Rapid decomplexation of bis(thiosemicarbazonato)zinc(II) complexes using citric acid; J. Chem. Res., 2008, 12, 702-703. DOI: 10.3184/030823408X380731.

 

12. Simon R. Bayly, Robert C. King, Davina J. Honess, Peter J. Barnard, Helen M. Betts, Jason P. Holland, Rebekka Hueting, Paul D. Bonnitcha, Jonathan R. Dilworth, Franklin I. Aigbirhio, and Martin Christlieb*; In vitro and in vivo evaluations of a hydrophilic 64Cu-bis(thiosemicarbazonato)–glucose conjugate for hypoxia imaging; J. Nucl. Med., 2008, 49, 1862-1868. DOI: 10.2967/jnumed.108.054015.

 

11. Helen M. Betts, Peter J. Barnard, Simon R. Bayly, Jonathan R. Dilworth,* Antony D. Gee and Jason P. Holland; Controlled axial ligation: solid-phase synthesis and purification of metallo-radiopharmaceuticals; Angew. Chem. Int. Ed., 2008, 47(44), 8416-8419. DOI: 10.1002/anie.200801936.

 

10. Jason P. Holland,* Peter J. Barnard, David Collison, Jonathan R. Dilworth,* Ruth Edge, Jennifer C. Green,* Julia M. Heslop, Eric J. L. McInnes, Christoph G. Salzmann and Amber L. Thompson; Synthesis, X-ray crystallography, spectroelectrochemistry and computational studies on potential copper-based radiopharmaceuticals; Eur. J. Inorg. Chem., 2008, 3549-3560. Highlighted as a “EurBest” article, 20th August 2008. DOI: 10.1002/ejic.200800413.

 

9. Jason P. Holland, Peter J. Barnard, Jonathan R. Dilworth,* and David J. Watkin; (2-Hydroxyphenylimido-κN)-(methanolate-κO)[2-oxidobenzylideneamino)phenlate-κ2O,N,O']-(triphenylphosphine-κP)rhenium(V); Acta Crystallogr. E, 2008, E64, m773. DOI: 10.1107/S1600536808010684.

 

8. Jason P. Holland,* Peter J. Barnard, David Collison, Jonathan R. Dilworth,* Ruth Edge, Jennifer C. Green,* and Eric J. L. McInnes; Spectroelectrochemical and computational studies on the mechanism of hypoxia-selectivity of copper radiopharmaceuticals; Chem. Eur. J., 2008, 14, 5890-5907. DOI: 10.1002/chem.200800539.

 

7. Jason P. Holland,* Peter J. Barnard, Simon R. Bayly, Helen M. Betts, Grant C. Churchill, Jonathan R. Dilworth,* Ruth Edge, Jennifer C. Green* and Rebekka Hueting; Synthesis, radiolabelling and confocal fluorescence microscopy of styrene derivatised zinc and copper bis(thiosemicarbazonato) complexes; Eur. J. Inorg. Chem., 2008, 1985-1993. DOI: 10.1002/ejic.200701351.

 

6. Peter J. Barnard, Simon R. Bayly, Jason P. Holland, Jonathan R. Dilworth* and Philip A. Waghorn; In vitro assays for assessing the stability of new potential copper-based radiopharmaceuticals; Q. J. Nucl. Med. Mol. Imaging, 2008, 52(3), 235-244. Link

 

5. Peter Barnard, Simon Bayly, Helen Betts, Paul Bonnitcha, Martin Christlieb, Jon Dilworth,* Jason Holland and Sofia Pascu; Towards new copper based radiopharmaceuticals; Q. J. Nucl. Med. Mol. Imaging, 2008, 52(2), 174-184. Link.

 

4. Andrey Y. Khalimon, Jason P. Holland, Radoslaw M. Kowalczyk, Eric J. L. McInnes, Jennifer C. Green, Philip Mountford* and Georgii Nikonov; Synthesis and molecular and electronic structure of an unusual paramagnetic borohydride complex Mo(NAr)2(PMe3)2(2-BH4); Inorg. Chem., 2008, 47, 999-1006. DOI: 10.1021/ic701826v.

 

3. Jason P. Holland, Franklin I. Aigbirhio, Helen M. Betts, Paul D. Bonnitcha, Paul Burke, Martin Christlieb, Grant C. Churchill, Andrew R. Cowley, Jonathan R. Dilworth,* Paul S. Donnelly, Jennifer C. Green, Josephine M. Peach, Sridhar R. Vasudevan and John E. Warren;Functionalized bis(thiosemicarbazonato) complexes of zinc and copper: Synthetic platforms towards site-specific radiopharmaceuticals; Inorg. Chem., 2007, 46, 465-485. DOI: 10.1021/ic0615628.

 

2. Jason P. Holland, Jennifer C. Green* and Jonathan R. Dilworth*; Probing the mechanism of hypoxia-selectivity of copper bis(thiosemicarbazonato) complexes: DFT calculation of redox potentials and absolute acidities in solution; Dalton Trans., 2006, 6, 783-794. DOI: 10.1039/b512656h. Highlighted as a “Hot Article” and reviewed in Chemistry World, January 2006.

 

1. Andrei S. Batsanov, Jonathan C. Collings, Ian J. S. Fairlamb,* Jason P. Holland, Judith A. K. Howard, Zhenyang Lin, Todd B. Marder,* Alex C. Parsons, Richard M. Ward, and Jun Zhu; Requirement for an oxidant in Pd/Cu co-catalyzed terminal alkyne homocoupling to give symmetrical 1,4-disubstituted 1,3-diynes; J. Org. Chem., 2005, 70, 703-706. DOI: 10.1021/jo048428u.